STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] ANI Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

ANI Pharmaceuticals (ANIP) Form 144 notice discloses a proposed sale of 6,937 common shares held by an insider through Morgan Stanley Smith Barney LLC, with an aggregate market value of $611,644.31 based on the filing. The shares represent a small portion of the company's outstanding common stock (21,688,772 shares outstanding) and the proposed sale is slated to occur on 08/18/2025 on NASDAQ.

The filing also lists the acquisition history for the shares being offered: 2,527 restricted shares acquired on 08/21/2024 and 4,410 restricted shares acquired on 05/21/2025, both issued by the company. No securities were reported sold by the person in the prior three months on this form, and the filer certifies that they have no undisclosed material adverse information.

Positive
  • Regulatory compliance: The filer submitted a complete Rule 144 notice including broker, share count, market value, and acquisition history
  • Transparency: Acquisition dates and number of restricted shares are disclosed, enabling clear tracing of grant origins
Negative
  • Insider sale: An affiliate intends to sell 6,937 shares valued at $611,644.31, which is a disposition of insider-held equity

Insights

TL;DR: Routine Rule 144 disclosure of insider sale; documentation aligns with restricted-stock vesting and brokerage placement.

The filing provides the required Rule 144 notice for a proposed sale of 6,937 shares through Morgan Stanley Smith Barney, documenting acquisition dates and that the shares were issued as restricted stock by the issuer. From a compliance perspective, the form contains the essential elements: broker details, number of shares, market value, outstanding shares, acquisition dates, and a certification regarding material nonpublic information. There are no reports of prior sales in the past three months, which simplifies aggregation questions under Rule 144(e).

TL;DR: Insider sale size is immaterial to capitalization; transaction appears administrative rather than market-moving.

The proposed sale equals roughly 0.032% of the reported outstanding common shares, indicating the transaction is unlikely to materially affect market supply or the company’s capitalization. The shares originated from restricted-stock issuances on two dates in 2024 and 2025, consistent with vesting/compensation events. The disclosure is standard for officer/affiliate liquidity events and contains no additional market-impacting details such as planned block trades or large-volume arrangements.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the ANIP Form 144 disclose?

This Form 144 discloses a proposed sale of 6,937 common shares through Morgan Stanley Smith Barney with aggregate market value of $611,644.31 and an approximate sale date of 08/18/2025.

How many ANIP shares are outstanding and what percentage does the sale represent?

The filing reports 21,688,772 shares outstanding; the proposed sale of 6,937 shares represents approximately 0.032% of outstanding common stock.

When were the shares being sold originally acquired?

The shares were acquired as restricted stock: 2,527 shares on 08/21/2024 and 4,410 shares on 05/21/2025.

Were there any other securities sold by this person in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

Through which broker will the ANIP shares be sold?

The broker named in the filing is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
Ani Pharmaceutic

NASDAQ:ANIP

ANIP Rankings

ANIP Latest News

ANIP Latest SEC Filings

ANIP Stock Data

1.76B
19.14M
10.42%
97.8%
9.42%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
BAUDETTE